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PDB11
DIFFERENCES IN HYPOGLYCEMIA EVENT RATES AND
ASSOCIATED COST-CONSEQUENCE IN PATIENTS INITIATED
ON LONG-ACTING AND INTERMEDIATE-ACTING INSULIN
PRODUCTS
Bullano MF1,Al-Zakwani I1, Barron JJ1, Menditto L2,Willey VJ1
1Health Core, Newark, DE, USA; 2Aventis Pharmaceuticals, Inc,
Parsippany, NJ, USA
OBJECTIVES: To compare hypoglycemia event rates and the
associated cost-consequence in patients initiated on long-acting
analogue insulin (glargine) or intermediate-acting insulins
(NPH). METHODS: This was a longitudinal administrative
claims database analysis from a managed care perspective using
a retrospective cohort design. Data were obtained from a large
southeastern US managed care plan with approximately 2.5
million quality data lives. All patients newly initiated on glargine
or NPH between July 1, 2000 and August 31, 2002 were iden-
tiﬁed (no use of glargine/NPH in the 4 months prior to index
date). Hypoglycemia event rates were identiﬁed by the presence
of medical claims with ICD-9-CM codes. Analyses were per-
formed using multivariable regression techniques. RESULTS:
The sample size was 1434 patients (glargine = 310, NPH =
1124). Mean age was 53 ± 17 years; 51.5% were male. Mean
treatment duration was 9 ± 4 months. After controlling for A1C
and other cogent demographic and clinical variables, patients in
the NPH cohort had a higher hypoglycemia event rate than the
glargine group (18.3 versus 7.3 per 100 patients/year; p = 0.009).
This event rate yielded a number-needed-to-treat of nine patients
(glargine versus NPH) to avoid one hypoglycemia event per
member per year (PMPY). Mean cost per hypoglycemia event
was $1087 (95% CI: $764–$1409). Mean annual index 
medication costs for the glargine cohort were $47 more PMPY
compared to the NPH cohort ($390 versus $343; p =
0.042). CONCLUSIONS: Patients treated with glargine had a
lower hypoglycemia event rate compared to NPH. The increased
cost associated with treating nine patients with glargine for 
one year (i.e., 9 ¥ $47 = $423) is less than the cost to treat one
hypoglycemic event ($1087).
PDB12
ESTIMATING THE REDUCTION IN LONG TERM
COMPLICATION AND COSTS OF COMPLICATIONS IN TYPE 1
DIABETES BY REDUCED A1C LEVELS DUE TO MORE
FREQUENT BLOOD GLUCOSE MONITORING
Nicklasson L1, Palmer AJ2, Roze S2
1Novo Nordisk Pharmaceuticals Inc, Princeton, NJ, USA; 2CORE
Center for Outcomes Research, Basel, Switzerland
OBJECTIVES: To simulate the impact of increased daily blood
glucose monitoring on risk of late complications for Type-1dia-
betes patients. METHODS: Previous studies have shown a rela-
tionship between increased daily blood glucose monitoring
(BGM) and reduced A1C levels for Type-1 diabetes patients. This
analysis quantiﬁes the reduced risk for complications and esti-
mates the lifetime costs for complications by modeling the effects
of BGM induced lower A1C levels over a lifetime. A standard
Monte Carlo simulation combining published literature for risk
of long-term diabetic complications with risk functions for each
complication was used. Clinical outcomes were based upon 
following diabetic complications: cardiovascular, neuropathy,
nephropathy, retinopathy, keto-and lacto acidosis and hypo-
glycemia. Lifetime costs for complications were calculated as the
yearly costs treating the different complications (US Medicare
perspective) over a 50-year period. Clinical outcomes and life-
time costs were discounted at 3%. Patient baseline data were
taken from a representative cohort of newly diagnosed type-1
diabetes patients. The effect of testing BG on A1C was taken
from published literature, which showed that the reduction in
A1C values from baseline was 0.70% (p < 0.001) by having one
daily BGM. Other studies have found similar reductions.
RESULTS: The difference in QALY was 0.46 years (LYG was
0.37 years) and lifetime cost was lower, due to fewer complica-
tions for the group with more frequent BGM ($54,800 vs.
$60,900 per patient over time). Furthermore, clinical outcomes
showed that the largest difference in reduced risk for complica-
tions was for nephropathy where the risk was reduced by more
than half in the group which did more BG test. Sensitivity analy-
ses support the validity and reliability of the results. CONCLU-
SIONS: This study showed the importance of BG testing on the
risk of complications for Type 1 diabetes patients. The reduced
risk for complications translates into less costs and thus less
burden for the patients and the society.
PDB13
PHARMACY AND MEDICAL RESOURCE UTILIZATION AMONG
INITIAL METFORMIN AND THIAZOLIDINEDIONE PATIENTS
Shaya FT1, Shin JY1, Mullins CD1, Foster S2, Fatodu H2
1University of Maryland, Baltimore, MD, USA; 2Johns Hopkins Health
care LLC, Glen Burnie, MD, USA
OBJECTIVE: To compare prescription and medical resource 
utilization by patients in Maryland Medicaid plans who are 
initiated on thiazolidinediones (TZDs) versus those initiated on
metformin. METHODS: This study includes a prospective non-
concurrent analysis of prescription and medical claims for Mary-
land Medicaid patients who were initiated on metformin or
TZDs between June 15, 2000 and June 15, 2002. We ran uni-
variate, bivariate, and multivariate models, examining the asso-
ciations between the likelihood of being initiated on a TZD and
age, gender, race, county of residence, coverage group, and days
supply, as well as variables to assess resource utilization: drug
count, total pharmacy claims, unique diagnoses count, and total
medical claims. Logistic regression models were used to assess
the combined effect of all utilization variables on the likelihood
of incident use of TZDs or metformin, adjusting for demo-
graphic variables. We also tracked the use of metformin and
TZDs in this population. RESULTS: The sample of 4440 patients
was mostly female (71.19%), older (52.58% over 49 years old)
and African American (58.84%). Patients with higher numbers
of unique diagnoses (OR = 1.6, p = 0.0071), prescription claims
(OR = 1.5, p = 0.0813), and unique drugs (OR = 1.7, p = 0.028)
were more likely to have received TZDs ﬁrst line. Those patients
with higher numbers of medical claims (OR = 0.5, p = 0.0029)
were less likely to have been started on TZDs. Among patients
started on metformin, 84% did not have subsequent use of
TZDs. Among those started on TZDs, 82% did not use 
metformin. CONCLUSIONS: Results show that patients initi-
ated on TZDs are more likely to have subsequently higher uti-
lization of prescription resources, even after adjusting for
demographic variables. These patients were also likely to use less
medical resources than metformin initial users.
PDB14
PROPENSITY SCORE METHODS FOR REDUCING BIAS IN THE
COMPARISON OF COSTS AND UTILIZATION BETWEEN
INSULIN LISPRO AND REGULAR INSULIN
Chen K1, Chang E1, Summers K2, Obenchain RL3,Yu-Isenberg K1,
Sun P3
1Prescription Solutions, Cost Mesa, CA, USA; 2Purdue University, West
Lafayette, IN, USA; 3Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVE: To compare results from two approaches—
propensity score binning or matching—for reduction of selection
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bias when comparing costs and utilization between insulin lispro
and regular human insulin users. METHODS: A retrospective
analysis of medical and pharmacy claims was conducted among
users of insulin lispro or regular insulin during the identiﬁcation
period, March 1, 2000 to February 28, 2001. Propensity scores
(PS) were estimated using age, gender, comorbidities, use of oral
antidiabetic medications, prescription copayment, and baseline
period diabetes-related costs and utilization. Our binning analy-
ses classiﬁed all patients into ﬁve PS strata (quintiles). Overall
cost and utilization differences during the 12-month follow-up
period were then calculated using weights inversely proportional
to variances of within bin differences. In our matched analyses,
all subjects who could not be “paired” (1 :1 lispro to regular
insulin) with PS estimates agreeing within ±0.0001 were
excluded. RESULTS: Of 6436 subjects, 1972 (30.6%) received
insulin lispro and 4464 (69.4%) received regular insulin. At
baseline, lispro subjects were younger, had fewer comorbidities,
and were less likely to use oral antidiabetic medications than
regular insulin users. Within PS quintiles, there was no signiﬁ-
cant imbalance on baseline characteristics. When matching, only
969 well-matched subject pairs could be retained. Baseline char-
acteristics of these well-matched subjects were similar to those
of subjects in quintiles 3 and 4, indicating that matching had
tended to exclude subjects with extreme combinations of char-
acteristics (quintiles 1 and 5). CONCLUSIONS: Relative to
matching, the binning approach to adjustment for treatment
selection bias appears to provide an answer that is more easily
generalized to our full diabetic population. The binning
approach uses all available outcome data to estimate overall
treatment differences. Our analyses suggest that restrictions on
insulin lispro availability to save pharmacy costs may not be 
economically justiﬁable from a more comprehensive payer’s 
perspective.
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TOTAL CHOLESTEROL, HDL CHOLESTEROL AND HBA1C
AFFECT QUALITY-ADJUSTED LIFE YEARS AND HOSPITAL
COSTS FOR PATIENTS WITH TYPE 2 DIABETES IN 
THE UNITED KINGDOM—THE CARDIFF DIABETES COST
UTILITY MODEL
McEwan P1, Peters JR2, Morrissey M3, Bergenheim K4, Currie CJ3
1Cardiff University, Cardiff, Wales, United Kingdom; 2University
Hospital of Wales, Cardiff, Wales, United Kingdom; 3Cardiff Research
Consortium, Cardiff, Wales, United Kingdom; 4AstraZeneca R&D
Mölndal, Mölndal, Sweden
OBJECTIVES: The Cardiff Diabetes Cost Utility Model is a dis-
crete-event stochastic simulation model used to model macrovas-
cular and microvascular complications in diabetes. The model
was based on the Eastman DCCT model, and forecasts costs and
outcomes over a 20-year period using the UKPDS risk engines
for estimating cardiovascular events. This study used the Cardiff
model to estimate quality-adjusted life years (QALYs) and cost
of secondary care for patients with type-2 diabetes. METHODS:
Health utility was incorporated via the EQ5D utility instrument
using estimates derived from the Health Outcomes Data Repos-
itory (HODaR). This diabetes model accurately incorporates
health utility estimates for patients with individual and multiple
complication states. The model was run using baseline risk pro-
ﬁles used by Eastman and was compared with a 10% change in
individual and combined modiﬁable risk factors. We evaluated
the impact of these changes on the costs of secondary care events,
excluding drug costs. Costs were discounted at 6% and beneﬁts
at 1.5%. RESULTS: At baseline, the total discounted cost of 
hospital events was £5841 (£3305 for cardiovascular events 
and £2536 for microvascular events). Following a 10% change
in one of three modiﬁable risk factors, hospital event costs and
QALYs gained were driven by the total cholesterol to high-
density lipoprotein cholesterol ratio (TC:HDL-C) (-£392; 0.23
QALYs) and glycated hemoglobin (HbA1c) level (-£1236; 0.44
QALYs). TC:HDL-C had the greatest impact on cardiovascular
costs (-£423), and HbA1c had the greatest impact on microvas-
cular costs (-£890). These results were dependent on the age of
the population modeled: as age increased, HbA1c had less impact
on events and costs and TC:HDL-C had more impact. CON-
CLUSIONS: This study further demonstrates the importance of
TC:HDL-C and HbA1c on cost of macro- and microvascular
complications, respectively. This economic model is the ﬁrst to
reliably evaluate beneﬁt in terms of health utility.
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THE ECONOMIC AND HEALTH OUTCOMES OF USING
DIFFERENT INSULIN DELIVERY DEVICES IN A MANAGED
CARE ENVIRONMENT
Liu X,Yu W,Yokoyama KK
WellPoint Pharmacy Management, West Hills, CA, USA
OBJECTIVES: To analyze the pharmacy and medical care 
costs of using different insulin-delivery methods, including pen-
injectors, disposable syringes, and traditional injection; and
examine the prevalence of hypoglycemic and hyperglycemic
events among patients on different delivery methods.
METHODS: Utilizing pharmacy and medical claims from a
managed care plan of over two million members, this study
selected continuously enrolled patients who received insulin or
insulin delivery products between July 1, 2000 and June 30,
2001, but did not have claims for these products in the six
months prior to the index date. The patients were divided into
three analysis groups based on initial insulin delivery method:
pen-injector, disposable syringe, or traditional injection. Phar-
macy and medical utilization, costs, and prevalence of hypo-
glycemic or hyperglycemic events in the 18 months following
index date were compared among the 3 groups. RESULTS:
Among the 3278 patients who received insulin products in the
12 months from July 1, 2000 to June 30, 2001, nearly 88% took
the traditional injection approach, only 12% adopted the deliv-
ery devices, including 146 patients (4.45%) who used pen injec-
tors and 250 patients (7.63%) who used disposable syringes.
Log-transformed linear regressions showed that pen-injector and
disposable users cost 58.5% and 50.3%, respectively, more than
patients using traditional injections in pharmacy expenditures,
but not in medical services expenditures, controlling for patient
demographics, comorbidities, community characteristics, and
type of health plan. Controlling for the same covariates, a logis-
tic regression indicated that the likelihood of having hypo-
glycemic or hyperglycemic events was similar between
traditional injection and the devices (p > 0.05). CONCLUSION:
This study did not ﬁnd signiﬁcant difference in medical costs and
insulin-related health events between patients who took insulin
via traditional injection and those adopted pen injectors or dis-
posable syringes, although traditional injections were less costly.
PDB17
RETIREE TYPE 2 DIABETES HEALTH CARE COSTS FOR A
SELF-INSURED TELECOMMUNICATIONS COMPANY
Erwin G1, Rajagopalan R2,Astuto J3,Wilson P4, Schaneman J5,
Kleinman N5
1Omnicare, Inc, King of Prussia, PA, USA; 2Takeda Pharmaceuticals
North America, Lincolnshire, IL, USA; 3Verizon Communications,
Alpharetta, GA, USA; 4Associates & Wilson, Rosemont, PA, USA;
5Options & Choices, Inc, Cheyenne, WY, USA
